Online Articles: Clinical and Laboratory ObservationsGanglioglioma in a Survivor of Infantile GlioblastomaScheuermann, Amanda DO*; Belongia, Meghan APNP*,†; Lawlor, Michael W. MD, PhD‡; Suchi, Mariko MD, PhD‡; Kaufman, Bruce MD§; Vasudevaraja, Varshini MSc∥; Serrano, Jonathan BSc∥; Snuderl, Matija MD∥; Knipstein, Jeffrey MD*,†Author Information Departments of *Pediatrics ‡Pathology and Laboratory Medicine §Neurosurgery †Division of Pediatric Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI ∥Department of Pathology, New York University, New York, NY M.W.L. is a member of advisory boards and receives research support from Audentes Therapeutics, Solid Biosciences, and Ichorion Therapeutics. M.W.L. is a consultant for Wave Life Sciences, Valerion Therapeutics, and Dynacure. The remaining authors declare no conflict of interest. Reprints: Amanda Scheuermann, DO, 8701 W Watertown Plank Road, Milwaukee, WI 53226 (e-mail: email@example.com). Received May 17, 2018 Accepted December 1, 2018 Journal of Pediatric Hematology/Oncology: January 2020 - Volume 42 - Issue 1 - p e56–e60 doi: 10.1097/MPH.0000000000001417 Buy Metrics Abstract Congenital tumors account for 2% to 4% of all pediatric central nervous system tumors. Glioblastoma multiforme (GBM) represents a small subset of these tumors. Despite harboring histologic features similar to older patients, infants with GBM exhibit improved survival and respond more favorably to surgery and chemotherapy. To highlight this tumor’s unique behavior, we report the case of a survivor of infantile GBM who developed a recurrent tumor in the surgical bed 6 months after diagnosis. The tumor was ultimately resected and was a ganglioglioma. This case shows both a favorable clinical outcome to an infantile GBM and this tumor’s natural history. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.